SlowBull
The Business Brief WEDNESDAY, 26 AUGUST 2026
← All stories
Markets

Spyre tumbles as immune drug misses mark in rheumatoid arthritis

1 source ·1 article ·2h ago

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·2h ago

Spyre tumbles as immune drug misses mark in rheumatoid arthritis

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.